Louisiana is currently home to 908 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
NCT06070350
Recruiting
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/27/2025
Locations: Tulane School of Medicine, New Orleans, Louisiana
Conditions: Hemorrhagic Shock, Trauma Injury
Register for Updates
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
NCT04647227
Recruiting
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/26/2025
Locations: Louisiana Center for Bleeding and Clotting Disorders, Tulane, New Orleans, Louisiana
Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Register for Updates
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628
Recruiting
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Louisiana Center for Bleeding and Clotting Disorders, Tulane University, New Orleans, Louisiana
Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Register for Updates
A Study to Assess Safety and Effectiveness of Injections of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Change of Mid-Face Volume
NCT06734351
Recruiting
Facial fullness is often regarded as a characteristic feature of a youthful face. Chronic reduction of collagen, elastin, and glycosaminoglycans contribute to the facial volume loss that characterizes the aging face. Volume restoration by replacing or augmenting soft tissue is critical to successful facial rejuvenation. NOA VOLUME is a crosslinked Hyaluronic Acid (HA) gel implant formulated with lidocaine that was developed to provide a safe, minimally invasive method of improving mid-face volum... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/25/2025
Locations: Pure Dermatology /ID# 258168, Metairie, Louisiana
Conditions: Mid Face Volume Deficit
Register for Updates
An INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY to ASSESS the PERFORMANCE of the CORDIO HEARO SYSTEM
NCT06378632
Recruiting
Study Design: This is an international, multicenter, observational, non-interventional, prospective, blinded, single-arm, two-period study, to collect patient utterances that will be retrospectively analyzed to determine the sensitivity and UPNR of the HearO system.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/25/2025
Locations: Cardiovascular Institute of the South, Houma, Louisiana
Conditions: Heart Failure
Register for Updates
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
NCT06065098
Recruiting
Cardiovascular disease (CVD) is the leading cause of death in the US general population. Although CVD mortality rates declined for both Black and White populations during the past two decades, they are still higher in Black adults than White adults. There are also persistent disparities in CVD risk factors with higher prevalence of obesity, hypertension, and diabetes in Black compared to White populations. In addition, CVD and risk factors are more prevalent in the residents of Louisiana compare... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/25/2025
Locations: Tulane University, New Orleans, Louisiana
Conditions: Cardiovascular Diseases, Hypertension, Diabetes, Hypercholesterolemia
Register for Updates
Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients
NCT04291105
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: Tulane University, Metairie, Louisiana
Conditions: Cystic Fibrosis
Register for Updates
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143
Recruiting
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/19/2025
Locations: Velocity Clinical Research, Lafayette, Lafayette, Louisiana
Conditions: Influenza, SARS-CoV-2
Register for Updates
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
NCT06559891
Recruiting
The primary objective of the THRIVE Pivotal study is to demonstrate the adjunctive effectiveness and the safety of the TIVUS system in: 1. subjects with hypertension (HTN) receiving up to 2 anti-hypertensive drugs of different classes in whom the anti-hypertensive medications will be stopped for a 4-week wash-out period before RDN/Sham procedure and during 2 months after procedure. 2. subjects with controlled hypertension receiving up to 2 anti-hypertensive drugs of different classes and who ac... Read More
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/19/2025
Locations: Cardiovascular Institute of the South, Houma, Louisiana
Conditions: Hypertension
Register for Updates
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
NCT06133322
Recruiting
The burden of hypertension and related cardiovascular diseases, stroke, and end-stage kidney disease is disproportionately high in Black populations, especially in the South. The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial aims to test the effectiveness, implementation, and sustainability of a community health worker (CHW)-led multifaceted intervention compared to enhanced usual care for hypertension control in Black communities. In... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Tulane University, New Orleans, Louisiana
Conditions: Hypertension
Register for Updates
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
NCT06835686
Recruiting
The goal of this clinical trial is to test the effectiveness of an evidence-based multi-level intervention for weight loss and the feasibility, fidelity, and sustainability of implementing the intervention in low-income and underserved people living with obesity in Louisiana. The main questions it aims to answer are: * Will an evidence-based multi-level obesity intervention (called LA-CEAL CONNECT) in adults living with obesity in low-income and underserved communities achieve weight loss at 6... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/17/2025
Locations: InclusivCare - Avondale Clinic, Avondale, Louisiana
Conditions: Obesity
Register for Updates